<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322708</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-014</org_study_id>
    <nct_id>NCT04322708</nct_id>
  </id_info>
  <brief_title>A Study of Antolimab (AK002) in Patients With Active Eosinophilic Esophagitis</brief_title>
  <acronym>KRYPTOS</acronym>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Antolimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to
      assess the efficacy and safety of antolimab (AK002) given monthly for 6 doses in adult and
      adolescent patients with active eosinophilic esophagitis. Subjects who complete the
      randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses
      of open-label antolimab (AK002) through the OLE Period of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who achieve esophageal intraepithelial eosinophil count of ≤6 eosinophils/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean absolute change in Dysphagia Symptom Questionnaire (DSQ) score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in esophageal intraepithelial eosinophil count</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving esophageal intraepithelial eosinophil count of ≤1 eosinophil/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving esophageal intraepithelial eosinophil count of ≤15 eosinophil/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment responders when a responder is a patient achieving &gt;30% reduction in symptoms (DSQ) and achieving a peak intraepithelial eosinophilic count of ≤6 eosinophils/hpf</measure>
    <time_frame>At Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &gt;50% reduction in DSQ score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in DSQ score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biweekly mean DSQ over time.</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in EoE Reference Score for Endoscopic Abnormalities (EREFS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg of antolimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of antolimab (AK002) (1mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/kg of antolimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of antolimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antolimab (AK002)</intervention_name>
    <description>Antolimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.</description>
    <arm_group_label>1 mg/kg of antolimab (AK002)</arm_group_label>
    <arm_group_label>3 mg/kg of antolimab (AK002)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female aged ≥12 and ≤80 years at the time of signing ICF.

          2. Confirmed diagnosis of EoE and esophageal intraepithelial eosinophilic infiltration of
             ≥15 eosinophils/hpf in 1 hpf from a biopsy collected during the Screening EGD without
             any other cause for the esophageal eosinophilia.

          3. History (by patient report) of an average of ≥2 episodes of dysphagia with intake of
             solid foods per week during the 4 weeks prior to Screening.

          4. Subjects must have failed or not be adequately controlled on standard of care
             treatments for EoE symptoms, which could include PPI, systemic or topical
             corticosteroids, and/or diet, among others.

          5. If on an allowed treatment for EoE, stable dose for at least 4 weeks prior to
             Screening and willingness to continue that dose for the study duration.

          6. If patient is on pre-existing dietary restrictions, willingness to maintain dietary
             restrictions throughout the study, as much as possible.

          7. Able and willing to comply with all study procedures.

          8. Female subjects must be either post-menopausal for at least 1 year with FSH level &gt;30
             mIU/mL at Screening or surgically sterile (tubal ligation,hysterectomy, or bilateral
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative
             pregnancy test and agree to use dual methods of contraception, or abstain from sexual
             activity from screening until the end of the study, or for 120 days following the last
             dose of study drug, whichever is longer. Male subjects with female partners of
             childbearing potential must agree to use a highly effective method of contraception
             from Screening until the end of the study or for 120 days following the last dose of
             study drug,whichever is longer. All fertile men with female partners of childbearing
             potential should be instructed to contact the Investigator immediately if they suspect
             their partner might be pregnant at any time during study participation.

        Key Exclusion Criteria:

          1. Concomitant EG, EoD, or eosinophilic colitis (EC).

          2. EG and/or EoD (≥30 eosinophils/hpf in 5 hpf in the stomach and/or ≥30 eosinophils/hpf
             in 3 hpf in the duodenum) as determined by central histology assessment of biopsies
             collected during the Screening EGD.

          3. Causes of esophageal eosinophilia other than EoE or one the following:
             hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, or
             peripheral blood absolute eosinophil count of &gt;1500 eosinophils/μL.

          4. History of inflammatory bowel disease, celiac disease, achalasia, and/or esophageal
             surgery.

          5. Any esophageal stricture unable to be passed with a standard diagnostic 9 mm to 10 mm
             upper endoscope or any critical esophageal stricture that requires dilation during
             screening.

          6. History of bleeding disorders or esophageal varices.

          7. History of malignancy; except carcinoma in situ, early stage prostate cancer, or
             non-melanoma skin cancers. However, cancers that have been in remission for more than
             5 years and are considered cured, can be enrolled (with the exception of breast
             cancer). All history of malignancy (including diagnosis, dates, and compliance with
             cancer screening recommendations) must be documented and certified by the
             Investigator, along with the statement that in their clinical judgment the tissue
             eosinophilia is attributable to EGID, rather than recurrence of malignancy.

          8. Active Helicobacter pylori infection (as determined by central histology staining of
             the biopsy collected during the Screening EGD), unless treated and confirmed to be
             negative prior to randomization and symptoms remain consistent.

          9. Positive Ova and Parasite (O&amp;P) test at Screening, seropositive for Strongyloides
             stercoralis at Screening, and/or treatment for a clinically significant helminthic
             parasitic infection within 6 months of Screening.

         10. Seropositive for HIV or hepatitis at Screening, except for vaccinated patients or
             patients with a history of hepatitis that has since resolved.

         11. Prior exposure to AK002 or hypersensitivity to any constituent of AK002.

         12. Change in dose of inhaled corticosteroids, nasal corticosteroids, PPI, and/or diet
             therapy within 4 weeks prior to Screening.

         13. Use of oral corticosteroids (swallowed topical or systemic corticosteroids) within 8
             weeks prior to Screening.

         14. Use of any biologics or medications that may interfere with the study, such as
             immunosuppressive or immunomodulatory drugs including azathioprine, JAK inhibitors,
             6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, anti-TNF, anti-IL-4
             receptor, e.g., dupilumab), anti-IL-5 (e.g., mepolizumab), anti-IL-5 receptor (e.g.,
             benralizumab), anti-IL-13 (e.g., lebrikizumab), anti-IgE (e.g., omalizumab), within 12
             weeks prior to Screening.

         15. Participation in a concurrent interventional study with the last intervention
             occurring within 30 days prior to administration of study drug or 90 days or 5
             half-lives, whichever is longer, for biologic products.

         16. Vaccination with live attenuated vaccines ≤30 days prior to initiation of treatment in
             the study, during the treatment period, or vaccination expected ≤5 half-lives (≤4
             months) following study drug administration.

         17. Treatment with chemotherapy or radiotherapy in the preceding 6 months.

         18. Presence of abnormal laboratory values considered by the Investigator to be clinically
             significant.

         19. Any disease, condition (medical or surgical), or cardiac abnormality, which in the
             opinion of the Investigator, would place the subject at increased risk.

         20. Known history of alcohol, drug, or other substance abuse or dependence.

         21. Women who are pregnant, breastfeeding, or planning to become pregnant while
             participating in the study.

         22. Any other reason that in the opinion of the Investigator or Medical Monitor makes the
             patient unsuitable for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Rasmussen, MD, PhD</last_name>
    <phone>443-699-5230</phone>
    <email>hrasmussen@allakos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>443-699-5230</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EoE</keyword>
  <keyword>Eosinophil</keyword>
  <keyword>Esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

